Issue link: https://www.e-digitaleditions.com/i/1543258
News on R&D and progress in the treatment of respiratory diseases, such as asthma and COPD, as well as articles on food allergy, air quality, public health, etc. Calendar: The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. 38 February 2026 Inhalation RESPIRATORY MEDICINE NEWS Allergy & Asthma Network joins US National Health Council FAIRFA X, VIRGINIA, US— PRNewswire reported that Allergy & Asthma Network (AAN) has joined the [United States] National Health Council (NHC), a coalition of nearly 200 national, health-related organizations. Allergy & Asthma Network is a national nonprofit voice in the US for people living with asthma, allergies and related conditions. Its programs focus on patient education, public awareness and policy advocacy to eliminate barriers to diagnosis and treatment, particularly among underserved communities. rough the NHC membership, AAN will engage in national initiatives that promote patient-focused research, equitable access to medications and improved care for chronic conditions. "We are honored to join the National Health Council and collaborate with other patient advocacy organizations committed to improving health equity and access to care," said Lynda Mitchell, CEO of Allergy & Asthma Network. "Our mem- bership strengthens our ability to bring positive change for peoples living with asthma, allergies and related conditions." CALENDAR Please visit the industry organi- zations page of the Inhalation website to find descriptions and contact information for cross- industry organizations and groups that present educational confer- ences and workshops. https://www.inhalationmag.com/ industry-organizations e collaboration aims to pro- vide targeted respiratory treat- ment for patients with severe viral infections, including critically ill patients requiring mechanical ventilation. Synairgen's INVENT study, a large, global Phase 2 clinical trial, is investigating SNG001 in mechanically venti- lated patients infected with a wide range of respiratory viruses such as influenza, respiratory syncytial virus, rhinovirus and COVID. e trial in the United States, United Kingdom and Europe is designed to address the urgent need for effective therapies in this high-risk population, where mor- tality rates remain unacceptably high. e partnership with Aero- gen seeks to ensure that SNG001 is delivered using a proven tech- nology, optimizing drug delivery and patient outcomes. 1nhaler secures additional funding for paper inhaler platform EDINBURGH, UNITED KING- DOM—1nhaler, a Scotland-based drug delivery device developer, announced it has secured an addi- tional £1.5 million in seed funding to drive development of its novel, pop-up, cardboard dry powder inhaler (DPI). e investment will enable 1nhaler to advance its plat- form technology towards a first Mar- keting Authorisation Application (MAA) targeted for late 2027. at would include the manufacture of clinical material for regulatory stud- ies and the design of large-scale com- mercial manufacturing processes. 1nhaler's DPI is made predomi- nantly from eco-friendly cardboard and is the size and shape of a credit card. e technology incorporates a patent-protected membrane-based system that transforms into a three- dimensional inhaler for patient use. e system can be tailored to effec- tively deliver different dry powder drugs. The company noted that performance data from 1nhaler's lead product demonstrated results on par with leading multidose dry powder inhalers. product approved for use outside of a hospital setting. "neffy has the potential to transform how severe allergies are treated, enabling earlier epinephrine use at the first signs of symptoms and reducing barriers that can delay care," said Rich- ard Lowenthal, co-founder, pres- ident and CEO of ARS Pharma. "We believe this innovation can meaningfully improve prepared- ness, confidence, and outcomes for patients and families across China." Synairgen and Aerogen announce partnership SOUTHAMPTON, UNITED KINGDOM AND GALWAY, IRELAND—Synairgen Research and Aerogen announced a stra- tegic partnership to develop and deliver a custom aerosol device for Synairgen's investigational therapy, SNG001 (inhaled inter- feron-beta), a broad-spectrum antiviral designed to boost the lungs' innate immune response. ADVERTISER INDEX C Copley Scientific 3 D DDL 5 I Intertek Cover 2 P Proveris 7 R RDD 1 S S-Matrix 9 INDUSTRY NEWS continued from page 8